Inactive Instrument

Highlights Crescita Therapeutics Inc. Other OTC

Equities

CRRTF

CA2258471028

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share	Mar. 13	MT
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	Mar. 13	CI
Crescita Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Crescita Therapeutics Brief: Q4 EPS Basic and Diluted Loss $0.01	Mar. 13	MT
Crescita Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	Nov. 08	CI
Crescita Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Crescita Therapeutics Obtains TSX Approval for Normal Course Issuer Bid	23-08-29	MT
Crescita Therapeutics Brief: Announced Approval of Normal Course Issuer Bid	23-08-29	MT
Crescita Therapeutics Inc. announces an Equity Buyback for 1,821,616 shares, representing 8.94% of its issued share capital.	23-08-29	CI
Crescita Therapeutics Inc. authorizes a Buyback Plan.	23-08-28	CI
- Crescita Therapeutics Brief: Q2 Revenue $5.162 Million; Ending cash was $10,226, down $49 for the quarter	23-08-09	MT
Crescita Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Crescita Therapeutics Inc. Announces Launch of Topical Anaesthetic Pliaglis(R) in Europe in Its European Core Markets Including Germany, the United Kingdom and Ireland	23-06-01	CI
Crescita Therapeutics Q1 Revenue was $4.6 Million; Cites Cash Balance of $10.3M	23-05-11	MT
Crescita Therapeutics Brief: Q1 Revenue was $4.602 Million; Cites Cash Balance of $10.3M	23-05-11	MT
Crescita Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Crescita Therapeutics Reports Q4 Revenue of $6.03 Million, EPS of $0.06	23-03-15	MT
Crescita Therapeutics Brief: Q4 Revenue was $6,030,000 compared to $7,562,000; Adjusted EBITDA was $997,000	23-03-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Crescita Therapeutics Inc. Other OTC

Equities

CRRTF

CA2258471028

Highlights

Filters